Decreased RNA-binding protein heterogeneous nuclear ribonucleoprotein U improves multiple myeloma sensitivity to lenalidomide.
drug sensitivity
hnRNPU
lenalidomide
mRNA translation
multiple myeloma
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
29 Apr 2024
29 Apr 2024
Historique:
revised:
20
03
2024
received:
08
12
2023
accepted:
03
04
2024
medline:
30
4
2024
pubmed:
30
4
2024
entrez:
30
4
2024
Statut:
aheadofprint
Résumé
Multiple myeloma (MM) is an incurable plasma cell cancer in the bone marrow. Immunomodulatory drugs, such as lenalidomide (LEN) and pomalidomide, are backbone agents in MM treatment, and LEN resistance is commonly seen in the MM clinic. In this study, we presented that heterogeneous nuclear ribonucleoprotein U (hnRNPU) affected MM resistance to LEN via the regulation of target mRNA translation. hnRNPU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Natural Science Foundation of China
ID : 82070219
Organisme : National Natural Science Foundation of China
ID : 81870157
Organisme : Faculty Start Fund
Organisme : Sichuan Natural Science Foundation
ID : 24NSFSC3229
Organisme : 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University
ID : ZYJC21007
Organisme : Key Research and Development Program of Sichuan Province
ID : 2023YFS0031
Organisme : National Key Research and Development Program of China
ID : 2022YFC2502600
Organisme : National Key Research and Development Program of China
ID : 2022YFC2502603
Organisme : National Natural Science Foundation of China
ID : 82370192
Informations de copyright
© 2024 British Society for Haematology and John Wiley & Sons Ltd.
Références
van de Donk N, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397(10272):410–427.
Barankiewicz J, Salomon‐Perzynski A, Misiewicz‐Krzeminska I, Lech‐Maranda E. CRL4(CRBN) E3 ligase complex as a therapeutic target in multiple myeloma. Cancers (Basel). 2022;14(18):4492.
Bird SA, Pawlyn C. IMiD resistance in multiple myeloma: current understanding of the underpinning biology and clinical impact. Blood. 2023;142:131–140.
Barrio S, Munawar U, Zhu YX, Giesen N, Shi CX, Viá MD, et al. IKZF1/3 and CRL4(CRBN) E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma. Haematologica. 2020;105(5):e237–e241.
Heintel D, Rocci A, Ludwig H, Bolomsky A, Caltagirone S, Schreder M, et al. High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. Br J Haematol. 2013;161(5):695–700.
Sperling AS, Burgess M, Keshishian H, Gasser JA, Bhatt S, Jan M, et al. Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs. Blood. 2019;134(2):160–170.
Nozawa RS, Boteva L, Soares DC, Naughton C, Dun AR, Buckle A, et al. SAF‐A regulates interphase chromosome structure through oligomerization with chromatin‐associated RNAs. Cell. 2017;169(7):1214–1227.e18.
Han BY, Liu Z, Hu X, Ling H. hnRNPU promotes the progression of triple‐negative breast cancer via RNA transcription and alternative splicing mechanisms. Cell Death Dis. 2022;13(11):940.
Shi ZD, Hao L, Han XX, Wu ZX, Pang K, Dong Y, et al. Targeting hnRNPU to overcome cisplatin resistance in bladder cancer. Mol Cancer. 2022;21(1):37.
Wang T, Hoekzema K, Vecchio D, Wu H, Sulovari A, Coe BP, et al. Large‐scale targeted sequencing identifies risk genes for neurodevelopmental disorders. Nat Commun. 2020;11(1):4932.
Goldman MJ, Craft B, Hastie M, Repečka K, McDade F, Kamath A, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38:675–678.
Yang Y, Gao Y, Huang J, Yang Z, Luo H, Wang F, et al. ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5. JCI Insight. 2022;7(19):e157081.
Yu T, Chaganty B, Lin L, Xing L, Ramakrishnan B, Wen K, et al. VIS832, a novel CD138‐targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo. Blood Cancer J. 2020;10(11):110.
Hideshima T, Ogiya D, Liu J, Harada T, Kurata K, Bae J, et al. Immunomodulatory drugs activate NK cells via both Zap‐70 and cereblon‐dependent pathways. Leukemia. 2021;35(1):177–188.
Cui Y, Wang F, Zhang D, Huang J, Yang Y, Xu J, et al. Estrogen‐responsive gene MAST4 regulates myeloma bone disease. J Bone Miner Res. 2022;37(4):711–723.
Gandin V, Sikström K, Alain T, Morita M, McLaughlan S, Larsson O, et al. Polysome fractionation and analysis of mammalian translatomes on a genome‐wide scale. J Vis Exp. 2014;87:51455.
Zheng Y, Wang Q, Li T, Qian J, Lu Y, Li Y, et al. Role of myeloma‐derived MIF in myeloma cell adhesion to bone marrow and chemotherapy response. J Natl Cancer Inst. 2016;108(11):djw131.
Ramos JM. Fluorescent in situ hybridization (FISH). Methods Mol Biol. 2022;2422:179–189.
Chang H, Jiang A, Qi C, Trieu Y, Chen C, Reece D. Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Leuk Lymphoma. 2010;51(11):2084–2091.
Zhu YX, Braggio E, Shi CX, Kortuem KM, Bruins LA, Schmidt JE, et al. Identification of cereblon‐binding proteins and relationship with response and survival after IMiDs in multiple myeloma. Blood. 2014;124(4):536–545.
An J, Ponthier CM, Sack R, Seebacher J, Stadler MB, Donovan KA, et al. pSILAC mass spectrometry reveals ZFP91 as IMiD‐dependent substrate of the CRL4(CRBN) ubiquitin ligase. Nat Commun. 2017;8:15398.
Haertle L, Barrio S, Munawar U, Han S, Zhou X, Vogt C, et al. Cereblon enhancer methylation and IMiD resistance in multiple myeloma. Blood. 2021;138(18):1721–1726.
Franssen LE, Nijhof IS, Couto S, Levin MD, Bos GMJ, Broijl A, et al. Cereblon loss and up‐regulation of c‐Myc are associated with lenalidomide resistance in multiple myeloma patients. Haematologica. 2018;103(8):e368–e371.
Huelga SC, Vu AQ, Arnold JD, Liang TY, Liu PP, Yan BY, et al. Integrative genome‐wide analysis reveals cooperative regulation of alternative splicing by hnRNP proteins. Cell Rep. 2012;1(2):167–178.
Zhou L, Xu G. The ubiquitination‐dependent and ‐independent functions of cereblon in cancer and neurological diseases. J Mol Biol. 2022;434(5):167457.
Gooding S, Ansari‐Pour N, Towfic F, Ortiz Estévez M, Chamberlain PP, Tsai KT, et al. Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma. Blood. 2021;137(2):232–237.
Krönke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343(6168):301–305.
D'Souza C, Prince HM, Neeson PJ. Understanding the role of T‐cells in the antimyeloma effect of immunomodulatory drugs. Front Immunol. 2021;12:632399.
Zhou N, Gutierrez‐Uzquiza A, Zheng XY, Chang R, Vogl DT, Garfall AL, et al. RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation. Leukemia. 2019;33(8):2006–2021.
Kortüm KM, Mai EK, Hanafiah NH, Shi CX, Zhu YX, Bruins L, et al. Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. Blood. 2016;128(9):1226–1233.
Zhu YX, Shi CX, Bruins LA, Wang X, Riggs DL, Porter B, et al. Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4. Blood Cancer J. 2019;9(2):19.
Bjorklund CC, Ma W, Wang ZQ, Davis RE, Kuhn DJ, Kornblau SM, et al. Evidence of a role for activation of Wnt/beta‐catenin signaling in the resistance of plasma cells to lenalidomide. J Biol Chem. 2011;286(13):11009–11020.
Liu J, Hideshima T, Xing L, Wang S, Zhou W, Samur MK, et al. ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment. Sci Adv. 2021;7(23):eabg2697.
Xiao R, Tang P, Yang B, Huang J, Zhou Y, Shao C, et al. Nuclear matrix factor hnRNP U/SAF‐A exerts a global control of alternative splicing by regulating U2 snRNP maturation. Mol Cell. 2012;45(5):656–668.
Yugami M, Kabe Y, Yamaguchi Y, Wada T, Handa H. hnRNP‐U enhances the expression of specific genes by stabilizing mRNA. FEBS Lett. 2007;581(1):1–7.
Tang X, Deng Z, Ding P, Qiang W, Lu Y, Gao S, et al. A novel protein encoded by circHNRNPU promotes multiple myeloma progression by regulating the bone marrow microenvironment and alternative splicing. J Exp Clin Cancer Res. 2022;41(1):85.
Fabbri L, Chakraborty A, Robert C, Vagner S. The plasticity of mRNA translation during cancer progression and therapy resistance. Nat Rev Cancer. 2021;21(9):558–577.
Bolomsky A, Hübl W, Spada S, Müldür E, Schlangen K, Heintel D, et al. IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide‐dexamethasone therapy in multiple myeloma. Am J Hematol. 2017;92(3):269–278.
Mougiakakos D, Bach C, Böttcher M, Beier F, Röhner L, Stoll A, et al. The IKZF1‐IRF4/IRF5 Axis controls polarization of myeloma‐associated macrophages. Cancer Immunol Res. 2021;9(3):265–278.
Chen LY, Gooding S. Tumor and microenvironmental mechanisms of resistance to immunomodulatory drugs in multiple myeloma. Front Oncol. 2022;12:1038329.
Krönke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, et al. Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. Nature. 2015;523(7559):183–188.
Fink EC, McConkey M, Adams DN, Haldar SD, Kennedy JA, Guirguis AA, et al. Crbn (I391V) is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice. Blood. 2018;132(14):1535–1544.
Röhner L, Ng YLD, Scheffold A, Lindner S, Köpff S, Brandl A, et al. Generation of a lenalidomide‐sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn(I391V). Exp Hematol. 2021;93:61–69.e4.